This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU
by Zacks Equity Research
A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September.
Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?
by Zacks Equity Research
The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US
by Zacks Equity Research
Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.
Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.
Should Oshares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSA
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $165.37, moving +0.25% from the previous trading session.
J&J (JNJ) Gets FDA Nod for 10M COVID Vaccines, Discards Many
by Zacks Equity Research
J&J (JNJ) gets authorization for two batches of COVID-19 vaccine doses manufactured at Baltimore facility but the FDA discards several others. Europe and Canada stop the rollout of some batches of the vaccine.
AstraZeneca (AZN) COVID-19 Jab's New Side Effect Stated by EMA
by Zacks Equity Research
The PRAC of the European Medicines Agency (EMA) has advised against giving AstraZeneca's (AZN) Vaxzevria COVID-19 vaccine to people with a history of capillary leak syndrome, a rare blood disorder.
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks
by Zacks Equity Research
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.
COVID-19 Jabs of Pfizer & Moderna May Lead to Inflamed Heart
by Indrajit Bandyopadhyay
The CDC reports cases of myocarditis and pericarditis following inoculation with mRNA vaccines of Moderna (MRNA) and Pfizer (PFE). The authority schedules meeting next week to investigate these reports.
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic
by Zacks Equity Research
Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
by Zacks Equity Research
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $163.39 in the latest trading session, marking a -0.88% move from the prior day.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
by Zacks Equity Research
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $166.20, moving +0.4% from the previous trading session.
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
by Zacks Equity Research
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection
by Zacks Equity Research
The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.
Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $168.81, marking a -0.15% move from the previous day.